Please login to the form below
Spark Therapeutics
This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
bluebird bio lodges counterclaim against Spark Therapeutics
bluebird bio has launched a counterclaim against Spark Therapeutics after the latter initiated a dispute a few months ago, according to Boston Business Journal. ... Spark Therapeutics is also developing a gene therapy for the potential treatment of
Latest news
-
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
As part of the collaboration, Dyno will be responsible for the design of the novel AAV capsids, while Roche and its Spark Therapeutics division will develop the capsids in preclinical studies, ... This new partnership represents Dyno’s largest
-
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
Also in the running is SPK-8011 from Spark Therapeutics – although this contender suffered a setback in 2018 after two patients treated with the therapy developed immune reactions.
-
Roche pays $1.15bn for Sarepta’s Duchenne gene therapy
Pens another gene therapy deal following takeover of Spark Therapeutics. Fresh from its drawn-out takeover of Spark Therapeutics, Roche has signed another gene therapy deal, licensing Sarepta’s Duchenne muscular
-
Roche to close $4.3bn Spark deal after FTC clearance
Comes on the heels of CMA green light. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following ... with and into Spark without a vote or meeting of Spark’s
-
UK’s CMA clears Roche’s $4.3bn takeover of Spark
Roche first announced deal in February. Its a happy day for Roche, as it clears one of the hurdles in the way of its $4.3 acquisition of Spark Therapeutics, after ... Adding Spark’s gene therapies SPK-8011 and earlier-stage follow-up SPK-8061 for
Roche to collaborate with Dyno on gene therapies for CNS/liver diseases
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
Roche pays $1.15bn for Sarepta’s Duchenne gene therapy
UK’s CMA clears Roche’s $4.3bn takeover of Spark
More from news
Approximately 18 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining
-
Alzheimer’s: the search for a cure
Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
-
Drug launches to watch in 2019
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
-
The European Medicines Agency: PRIME’d for access?
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Alzheimer’s: the search for a cure
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Drug launches to watch in 2019
The European Medicines Agency: PRIME’d for access?
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Industry appointments
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and
Industry appointments
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Mind+Matter
Spark Therapeutics, Superdrug, Thornton &Ross, Vetoquinol, VMIC, Zogenix.
Mind+Matter
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
-
Digital strategist
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- EU approves bluebird bio’s CALD gene therapy Skysona
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Onyx Health Launch Creative Studio After Record Year
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
- Positive prospects for pharma in Latin America
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Biosimilars in China
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
